Human Fc epsilon RI alpha Protein, His Tag (MALS verified)
分子別名(Synonym)
FCER1A, FCE1A, FcERI
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human Fc epsilon RI alpha, His Tag (FCA-H5228) is expressed from human 293 cells (HEK293). It contains AA Val 26 - Gln 205 (Accession # P12319-1).
Predicted N-terminus: Val 26
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.9 kDa. The protein migrates as 37-55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method / rFC method.
純度(Purity)
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.

背景介紹
高親和力免疫球蛋白ε受體α亞基(FCER1A)亦稱為Fc-epsilon RI-alpha(FcERI)、IgE Fc受體α亞基、FCE1A。該蛋白包含兩個(gè)免疫球蛋白樣(Ig樣)結(jié)構(gòu)域,能夠特異性結(jié)合免疫球蛋白ε的Fc區(qū)段,是一種高親和力受體。FCER1A在啟動(dòng)變態(tài)反應(yīng)中起核心作用:當(dāng)過敏原與受體結(jié)合的IgE結(jié)合后,可誘發(fā)細(xì)胞活化并釋放組胺等介質(zhì),從而引發(fā)過敏反應(yīng)臨床表現(xiàn)。該受體同時(shí)能誘導(dǎo)重要淋巴因子的分泌,通過耦聯(lián)過敏原與肥大細(xì)胞,啟動(dòng)炎癥反應(yīng)和速發(fā)型超敏反應(yīng),在花粉癥、哮喘等過敏性疾病的發(fā)病機(jī)制中發(fā)揮關(guān)鍵作用。
關(guān)鍵字: FCER1A;FCER1A蛋白;FCER1A重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。